English
Français
Our advanced gene therapy technology capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.
Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.
Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
News, press releases, and more.
Cash and cash equivalents of €15.0 million1 as of 30 June 2021 Paris, France —…
Paris, France — 08 July 2021 at 06:00 pm CET — Lysogene (FR0013233475 – LYS),…
Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS),…
Shareholders approved all proposed resolutions Paris, France — 25 June 2021 at 06:00 pm CEST…
Strengthening of Lysogene’s pipeline with a new drug candidate for a pathology with high unmet…
Second Lysogene CNS gene therapy program to enter the clinic Ongoing enrollment of a total…
Paris, France — 20 May 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS),…
Cash and cash equivalents of €20.0 million* as of 31 March 2021 Paris, France —…
Paris, France — 13 April 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…
Positive biomarker data reported with LYS-SAF302 for the treatment of MPS IIIA New program entering…
Valuable information designed to provide knowledge and insights to patients, families, and caregivers.
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.
GM1 gangliosidosis, or Landing disease, is a rare inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.
Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.
Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.
